Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Abbott, AstraZeneca cholesterol combo

  • News

Executive Summary

Abbott and AstraZeneca have decided to pursue development of a combination of Abbott's next-generation fenofibrate ABT-335 with AstraZeneca's Crestor (rosuvastatin), the firms announce Aug. 31. The partnership to develop a multi-targeted fenofibrate/statin cholesterol combination was announced last year. However, the companies had not determined whether the product would use the investigational ABT-335 or Abbott's marketed drug, TriCor (fenofibrate). Abbott and AstraZeneca are targeting 2009 for submitting an NDA for the combination, which is expected to offer the LDL-C lowering benefits of Crestor and the HDL-C raising and triglyceride-lowering benefits of fibrates. Based on positive clinical trial results, Abbott also said it will file ABT-335 as monotherapy by year-end...

Table

View full table

Tags:
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS048734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By